

RECEIVED
CENTRAL FAX CENTER

SEP 13 2006

AMENDMENTS TO THE CLAIMS

Please amend Claims 32 and 33 as indicated below.

Claims 1-30 (canceled).

Claim 31 (previously presented): An MN antisense construct comprising a nucleic acid sequence from which an MN antisense oligonucleotide is transcribable, wherein said nucleic acid sequence is operably linked to an expression control sequence in a vector, wherein said MN antisense oligonucleotide is complementary to SEQ ID NO: 5, and wherein said MN antisense construct shows antisense activity in an in vitro screening assay comprising the steps of:

- a) contacting a human cell abnormally expressing MN with said MN antisense construct;
- b) determining the effect of said MN antisense construct on MN expression in said human cell; and
- c) concluding that if MN expression is decreased, that said MN antisense construct shows antisense activity.

Claim 32 (currently amended): The MN antisense construct of Claim 31, wherein said MN antisense ~~nucleotide~~ oligonucleotide is complementary to the 5' end of the mRNA that is transcribed from the complement of SEQ ID NO: 5.

Claim 33 (currently amended): The MN antisense construct of Claim 31, wherein said MN antisense ~~nucleotide~~ oligonucleotide is complementary to SEQ ID NO: 1.

Claim 34 (previously presented): The MN antisense construct of Claim 31, wherein said vector is derived from a plasmid, a cosmid, a bacteriophage or a virus.

Claim 35 (previously presented): A composition comprising a pharmaceutically acceptable carrier and the MN antisense construct of claim 31, wherein said MN antisense construct interacts with MN gene or MN transcript.

Claim 36-38: (canceled)

Claim 39 (withdrawn): A method of blocking in vivo expression of the MN gene in a human by administering an MN antisense construct of claim 31.

Claim 40 (withdrawn): A method of treating neoplastic disease and/or pre-neoplastic disease in a human, wherein said disease is associated with abnormal MN gene expression,

comprising inhibiting the expression of MN gene by administering an MN antisense construct according to claim 31.

Claim 41 (withdrawn): An antibody which specifically binds to an MN protein or to an MN polypeptide, wherein said MN protein or MN polypeptide is encoded by a nucleic acid that comprises a polynucleotide containing at least 29 nucleotides, said nucleic acid being selected from the group consisting of:

- (a) SEQ ID NO: 5;
 - (b) polynucleotides that hybridize under stringent conditions to SEQ ID NO: 5's complement; and
 - (c) polynucleotides that differ from SEQ ID NO: 5 or from the polynucleotide sequences of (b) due to the degeneracy of the genetic code,
- and wherein said antibody is polyclonal.

Claim 42 (withdrawn): The antibody of Claim 41 that is conjugated to a toxin.

Claim 43 (withdrawn): The antibody of Claim 41 that is conjugated to a chemotherapeutic drug.

Claim 44 (withdrawn): An antibody which specifically binds to an MN protein or to an MN polypeptide, wherein said MN

protein or MN polypeptide is encoded by a nucleic acid that comprises a polynucleotide containing at least 29 nucleotides, said nucleic acid being selected from the group consisting of:

- (a) SEQ ID NO: 5;
- (b) polynucleotides that hybridize under stringent conditions to SEQ ID NO: 5's complement; and
- (c) polynucleotides that differ from SEQ ID NO: 5 or from the polynucleotide sequences of (b) due to the degeneracy of the genetic code,

and wherein said antibody is humanized.

Claim 45 (withdrawn): The antibody of Claim 44 that is conjugated to a toxin.

Claim 46 (withdrawn): The antibody of Claim 44 that is conjugated to a chemotherapeutic drug.

Claim 47 (withdrawn): The antibody of Claim 41 wherein said polyclonal antibody specifically binds to an MN antigen epitope selected from the group of epitopes represented by the following amino acid sequences: SEQ. ID. NOS. 10-16.

Claim 48 (withdrawn): An antibody according to Claim 47 wherein said sequences are SEQ. ID. NOS.: 10, 11 and 12.

Claim 49 (withdrawn): An antibody according to Claim 47 wherein said MN antigen epitope is SEQ. ID. NO.: 10.

Claim 50 (withdrawn): The antibody of Claim 44 wherein said humanized antibody specifically binds to an MN antigen epitope selected from the group of epitopes represented by the following amino acid sequences: SEQ. ID. NOS. 10-16.

Claim 51 (withdrawn): An antibody according to Claim 50 wherein said sequences are SEQ. ID. NOS.: 10, 11 and 12.

Claim 52 (withdrawn): An antibody according to Claim 50 wherein said MN antigen epitope is SEQ. ID. NO.: 10.

Claim 53 (previously presented): The MN antisense construct of claim 31, wherein said promoter comprises a nucleic acid sequence derived from the MN promoter.

Claim 54 (previously presented): The MN antisense construct of Claim 31, wherein said MN antisense oligonucleotide is between 19 and 29 nucleotides in length.

Claim 55 (previously presented): The MN antisense construct of Claim 31, wherein said MN antisense oligonucleotide is selected from the group consisting of SEQ ID NOS: 3, 4 and 7.